Why buy this course?

The course you are looking at is not like any other e-Learning course you have ever taken. Watch this short video to learn why!

Telemedicine Prescribing of Controlled Substances: Fourth Temporary Extension through 2026

$129.99

Stay ahead of regulatory changes with this targeted training on the DEA and HHS’s Fourth Temporary Extension for telemedicine prescribing of controlled substances. Learn the specific compliance steps, practitioner obligations, and technology standards needed to prescribe Schedules II-V medications remotely through December 31, 2026. Gain clarity on the interaction with other DEA/HHS rules and the enforcement risks of non-compliance. Ensure uninterrupted patient care and avoid costly penalties during this critical regulatory transition.

In this course you will learn the following:
* Understand the background and legal authority for the temporary extension of telemedicine flexibilities.
* Identify the specific requirements and conditions for prescribing controlled substances via telemedicine under the Fourth Temporary Rule.
* Implement actionable steps to ensure compliance with the rule’s requirements and deadlines.
* Recognize the interaction between this temporary rule and other related DEA/HHS rules.
* Understand the legal and financial consequences of non-compliance.

NOTE: Unless otherwise indicated, all course purchases are for access to the course for a period of 1-year.  At the end of the one year term, the course will be set to “inactive”. 

Why This Course is Important
Without this course, practitioners risk non-compliance, potential loss of prescribing authority, and disruption in patient care as telemedicine regulations shift for controlled substances through 2026.

Course Details
This is a self-paced eLearning course based on the Federal Register Document titled Fourth Temporary Extension of COVID-19 Telemedicine Flexibilities for Prescription of Controlled Medications.

Key regulatory references include:

Course SKU
FR-25-1659-1